El interés en corto de Biodexa Pharmaceuticals da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Biodexa Pharmaceuticals. Los datos de interés en corto se actualizan cada dos semanas.

Biodexa Pharmaceuticals (NASDAQ:BDRX) Bolsa, Informe de interés en corto

Biodexa Pharmaceuticals

Biodexa Pharmaceuticals PLC is a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines. The company combines approved and developed medications with its proprietary and drug delivery technologies to provide compelling products that have the potential to powerfully impact the lives of patients.

Biodexa Pharmaceuticals plc - American Depositary Shares

Biodexa Pharmaceuticals PLC

BOMBARDIER 6.25% PFD A by Bombardier Inc.

Bombardier Inc

Alamos Gold (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGI#NYSE">AGI</a>) has outperformed the market over the past 5 years by 19.39% on an annualized basis producing an average annual return of 35.71%. Currently, Alamos Gold has a market capitalization of $11.10 billion. 
Buying $1000 In AGI: If an investor had bought $1000 of AGI stock 5 years ago, it would be worth $4,578.58 today based on a price of $26.39 for AGI at the time of writing.
<h3>Alamos Gold's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743634872_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

$1000 Invested In Alamos Gold 5 Years Ago Would Be Worth This Much Today

A recent <a href="https://www.youtube.com/watch?v=tZs3k3t3k5g">call</a> on &#8220;The Ramsey Show,&#8221; hosted by George Kamel and Jade Warshaw, took a sharp turn after a listener asked a seemingly straightforward question about <a href="https://www.benzinga.com/news/25/02/43888952/americans-owe-a-record-1-21-trillion-in-credit-card-debt-expert-warns-theres-no-end-in-sight">credit card debt</a>.
The caller wanted to know if he should focus on paying off <a href="https://www.benzinga.com/money/best-0-apr-credit-card">credit cards with 0% interest</a> but high balances, or the ones with higher interest rates and smaller balances.
<h2 class="wp-block-heading">Debt Snowball vs. Avalanche</h2>
Kamel jumped in: "It's simple but it's hard to grasp and to fully just take action on," he said. &#8220;The math says why would you knock out the highest interest first because you&#8217;re saving the most money, right? But what we've found is that people who actually successfully get out of debt once and for all do it using the debt snowball method.&#8221;
Don't Miss:
<ul>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
<li><a href="https://www.benzinga.com/money/arrived-private-credit-fund">Bezos' Favorite Real Estate Platform Launches A Way To Ride The Ongoing Private Credit Boom</a></li>
</ul>
Instead of focusing on interest rates, the <a href="https://www.benzinga.com/personal-finance/25/03/44494260/dave-ramsey-reveals-how-to-rebound-from-financial-setbacks-if-youre-over-40-and-feeling-behind-its-not-too-late-but-youd-better-get-serious">debt snowball method</a> prioritizes paying off the smallest balances first. &#8220;You can cross out the interest rate. Imagine it doesn't exist—0% or 50%, just pay off the smallest balance first,&#8221; said Kamel. The idea is that paying off smaller balances first builds momentum and helps change behavior, which is what ultimately gets people out of debt.
The conversation took a turn when the caller revealed he had more than $220,000 in total debt—excluding his mortgage. That included $15,000 in credit cards, $18,000 in business debt, and about $80,000 in auto loans.
Trending: Many are using retirement income calculators to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on what&#8217;s behind this formula.</a>
Kamel was floored. "You make $60,000 a year and you owe $80,000 in auto loans?" she asked. The caller explained that he had recently bought a new Kia, owing $53,000 on it, even though it's now worth only about $45,000. The payment is $757 a month.
"And you thought, &#8216;Man, I'm taking them to the cleaners on this one!&#8217;" Kamel joked, clearly in disbelief.
As it turned out, the man also owed $30,000 on a minivan worth only $20,000. Between both cars, the payments were choking his monthly budget. "You are sinking because of these cars," Warshaw said bluntly. "Both of these cars need to go today."
See Also: <a href="https://www.benzinga.com/money/suze-orman-retirement-bucket">&#8216;Which Bucket Do I Draw From First?&#8217; Suze Orman Explains To 67-Year-Old The Best Order For Tapping Into Her Retirement Accounts</a>
Outside of the vehicle debt, the caller had a complicated financial story: He had recently lost his father, gone through probate without a will, inherited a home he's now paying $1,200 a month for, and is supporting his fiancée and their three babies under two years old on a single income. He also mentioned <a href="https://www.benzinga.com/partner/emerging-markets/25/02/43558102/monalee-slashes-the-cost-of-rooftop-solar-panels-with-its-tech-driven-offering">solar panels</a> costing $300 a month that he didn't want in the first place.
Despite all of this, he had managed to save $1,000—Baby Step 1 in the Ramsey plan—and was bringing in an extra $2,000 to $3,000 a month from a side hustle. His fiancée, a stay-at-home mom, also earns a few hundred dollars promoting hair care products through a multi-level marketing company.
But Kamel warned against counting on the MLM income. "Google the disclosure statement for this company," he said. They legally have to disclose how many people make money. &#8220;I don't think this is the way out for you guys.&#8221;
Read Next:
<ul>
<li>BlackRock is calling 2025 the year of alternative assets. <a href="https://www.benzinga.com/money/masterworks">One firm from NYC has quietly built a group of 60,000+ investors who have all joined in on an alt asset class previously exclusive to billionaires like Bezos and Gates.</a></li>
<li><a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a></li>
</ul>

Dave Ramsey Caller Asks About Paying Off Credit Cards—But Gets Roasted For Owing $52,000 On A Kia—'You're Sinking Because Of These Cars'

Kimco Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KIM#NYSE">KIM</a>) has outperformed the market over the past 5 years by 2.26% on an annualized basis producing an average annual return of 18.58%. Currently, Kimco Realty has a market capitalization of $14.22 billion. 
Buying $100 In KIM: If an investor had bought $100 of KIM stock 5 years ago, it would be worth $247.69 today based on a price of $20.93 for KIM at the time of writing.
<h3>Kimco Realty's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743633954_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Kimco Realty 5 Years Ago Would Be Worth This Much Today

Entrepreneur and investor Mark Cuban is one of several backers of a pre-seed round of Skylight, a startup seeking to rival TikTok, an app that could have new owners in the<a href="https://www.benzinga.com/general/social-media/25/04/44599624/tiktok-clock-ticks-louder-as-deadline-approaches-trump-to-consider-final-proposal-as-private-equity-firms-bid-for-platform"> U.S. soon.</a>
What Happened: Skylight uses the AT Protocol, the same technology that helps social network Bluesky, which is<a href="https://www.benzinga.com/general/social-media/24/12/42566461/mark-cuban-says-this-is-the-holy-grail-that-makes-bluesky-better-than-musks-x-platform"> one of Cuban's favorites.</a>
The startup released its mobile app publicly Tuesday after 10 weeks of development, as reported by <a href="https://techcrunch.com/2025/04/01/mark-cuban-backs-skylight-a-tiktok-alternative-built-on-blueskys-underlying-technology/">TechCrunch</a>.
The short-form video app was developed by co-founder Tori White and Reed Harmeyer. The duo said Skylight features in-app video editing tools, public comments and likes along with the ability to set up user profiles and follow other users.
Since the app is built on the AT Protocol, Skylight can also be seen and engaged with by the more than 33 million existing Bluesky users.
Cuban funded a pre-seed round for Skylight. Graham &amp; Walker Venture Fund was also an investor in the round.
Read Also: <a href="https://www.benzinga.com/general/social-media/25/04/44598279/hillary-clinton-barack-obama-join-bluesky-posts-take-aim-at-elon-musks-efforts-in-wisconsin-here-are-the-top-10-most-followed-accounts">Hillary Clinton, Barack Obama Join Bluesky, Posts Take Aim At Elon Musk&#8217;s Efforts In Wisconsin: Here Are The Top 10 Most Followed Accounts</a>
Why It's Important: White and Hermeyer said they were inspired to create Skylight when news of TikTok being banned in the U.S. broke.
While the potential TikTok ban is on pause as a buyer is shopped for, Skylight could be set to benefit from being ban-proof by using the underlying Bluesky technology, for the decentralized social media network.
White was a travel influencer worried about losing all of her past TikTok videos, which she has backed up. While she may have the videos, she fears that she could lose the comments and access to her community following she built.
Skylight supports video uploads like TikTok, but also wants to make sure users can customize their feed in the future, giving creators more control. This could include sounds, duets, stitching, bookmarks, playlists and more, according to the report.
Cuban previously said he was interested in backing apps similar to TikTok and are created with Bluesky in mind.
The Skylight app is available in the Google Play Store and Apple&#8217;s iOS store. 
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/entertainment/25/03/44522293/shark-tank-poll-reveals-most-polarizing-star-is-it-mark-cuban">&#8216;Shark Tank&#8217; Poll Reveals Most Polarizing Star — Is It Mark Cuban?</a></li>
</ul>
Photo: Shutterstock

Social Media

Financing

Tech

Mark Cuban Backs TikTok Rival That Uses BlueSky Technology: How Skylight Is Changing The Game

Globus Medical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMED#NYSE">GMED</a>) has outperformed the market over the past 10 years by 1.08% on an annualized basis producing an average annual return of 11.62%. Currently, Globus Medical has a market capitalization of $10.38 billion. 
Buying $100 In GMED: If an investor had bought $100 of GMED stock 10 years ago, it would be worth $294.81 today based on a price of $75.50 for GMED at the time of writing.
<h3>Globus Medical's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743633044_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

GMED

$100 Invested In Globus Medical 10 Years Ago Would Be Worth This Much Today

Back in 2009, during a <a href="https://charlierose.com/videos/22046">sit-down with Charlie Rose</a> in the wake of the financial crisis, Warren Buffett made his stance on cash loud and clear: he wasn't a fan.
"<a href="https://www.benzinga.com/personal-finance/24/05/38592657/warren-buffett-warns-cash-is-always-a-bad-investment-because-its-sure-to-go-down-in-value-having">Cash is always a bad investment</a>," he told Rose. "When people say ‘cash is king,' that's crazy… It was sure to go down in value over time." He compared it to oxygen — necessary, but only in reasonable doses saying, "You don't need to have excessive amounts of it around." He also added, "Anytime we have surplus cash around, I'm unhappy. I would much rather have good businesses than cash."
Don't Miss:
<ul>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
<li>Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die."<a href="https://www.benzinga.com/money/warren-buffet-make-money-when-you-sleep"> Here&#8217;s how you can earn passive income with just $100.</a></li>
</ul>
Fast forward to 2025, and the chairman of Berkshire Hathaway (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>, BRK.B)) is now sitting on a record-shattering $334.2 billion in cash — more than the company's stock portfolio, which shrank to $272 billion last year, <a href="https://fortune.com/2025/03/15/warren-buffett-berkshire-hathaway-stock-market-correction-cash-pile-acquisitions/">according to Fortune</a>. That's nearly double the cash pile from the year before.
So, what gives?
According to Buffett, nothing's changed in terms of philosophy. In his <a href="https://www.berkshirehathaway.com/2024ar/2024ar.pdf">most recent letter to shareholders</a>, he emphasized that "Berkshire will never prefer ownership of cash-equivalent assets over the ownership of good businesses."&nbsp;
But unfortunately, those good businesses are&nbsp; getting harder to find.
Trending: The secret weapon in billionaire investor portfolios that you almost certainly don't own yet. <a href="https://www.benzinga.com/money/masterworks">See which asset class has outpaced the S&amp;P 500 (1995-2024) – and with near-zero correlation.</a>
In <a href="https://www.berkshirehathaway.com/letters/2023ltr.pdf">last year's letter</a>, Buffett had already set expectations, noting that the days of "eye-popping" returns at Berkshire were likely behind them. "There remain only a handful of companies in this country capable of truly moving the needle at Berkshire," he wrote. "And they have been endlessly picked over by us and by others."
Translation? There's not much out there worth writing a big check for. Even outside the U.S., Buffett sees "essentially no candidates that are meaningful options" for deploying capital. So instead of chasing overpriced deals, he's parking the cash and waiting.
Which brings it back to another classic Buffettism: "<a href="https://www.benzinga.com/markets/25/03/44533852/what-would-buffett-do-with-markets-inches-away-from-the-extreme-fear-zone-is-it-finally-time-to-be-greedy">Be fearful when others are greedy</a>, and greedy when others are fearful."
See Also: <a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.
Right now, fear is floating in the air — inflation remains sticky, interest rates are still high, and the stock market's looking a little overcaffeinated. That might explain why Buffett is <a href="https://www.benzinga.com/news/earnings/25/02/43903272/buffetts-assures-berkshire-hathaway-shareholders-amid-skyrocketing-cash-reserves">choosing patience over action</a>. After all, a deal-hunter doesn't rush the aisle unless the sale signs are flashing.
To be clear, Buffett hasn't suddenly fallen in love with cash. He's just not going to force-feed billions into subpar investments to stay busy. And with Berkshire's size, it takes a really big fish to move the needle — not just any publicly traded guppy.
So yes, cash might still be a "bad investment" in Buffett's eyes. But sometimes, sitting still is the smartest move in the room — especially when you're holding $334 billion and waiting for the right moment to pounce.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/money/mark-cubans-advice-for-lotto-winners">Many are surprised by Mark Cuban's advice for lotto winners: Cash or annuity?</a></li>
<li>These five entrepreneurs are worth $223 billion –<a href="https://www.benzinga.com/money/arrived-homes-private-credit-fund"> they all believe in one platform that offers a 7-9% target yield with monthly dividends</a></li>
</ul>

Personal Finance

Warren Buffett Said 'Cash Is Always A Bad Investment' And You Don't Need 'Excessive Amounts'  — But He's Sitting On Record $334 Billion Cash Pile

The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), which tracks the S&amp;P 500, is facing heavy selling pressure in Wednesday&#8217;s after-hours session following reciprocal tariffs<a href="https://www.benzinga.com/government/regulations/25/04/44618089/trumps-tariffs-surprise-triggers-carnage-magnificent-7-set-to-wipe-out-nearly-700-billion-in-market-value"> from the Trump Administration</a>.
What To Know: U.S. President Donald Trump unveiled sweeping new tariffs on Wednesday designed to help strengthen the American economy over the long term. The move could have dramatic impacts on the economy in the near term, as evidenced by the steep sell-off in reaction by the market.
The SPY was last down about 2.8% after hours, trading just below the $550 level. With a market capitalization of approximately $47.36 trillion as of April 1, <a href="https://www.slickcharts.com/sp500/marketcap#:~:text=The%20S%26P%20500%20has%20a,the%20outstanding%20float%20share%20count.">per</a> Slickcharts, the S&amp;P 500 saw approximately $1.3 trillion in value disappear on Wednesday.
Here&#8217;s a look at some of the biggest movers in the S&amp;P 500 after hours:
<ul>
<li>On Holding AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONON#NYSE">ONON</a>) down 15.01% at $38.22</li>
</ul>
<ul>
<li>Five Below Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVE#NASDAQ">FIVE</a>) down 13.5% at $70.49</li>
</ul>
<ul>
<li>AST SpaceMobile Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>) down 11.2% at $19.90</li>
</ul>
<ul>
<li>Dollar Tree Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>) down 11.1% at $68.99</li>
</ul>
<ul>
<li>Lululemon Athletica Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) down 10.9% at $251.96</li>
</ul>
<ul>
<li>Deckers Outdoor Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DECK#NYSE">DECK</a>) down 10.1% at $106.05</li>
</ul>
<ul>
<li>Skechers U.S.A. Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKX#NYSE">SKX</a>) down 9.59% at $53.38</li>
</ul>
<ul>
<li>Shopify Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHOP#NASDAQ">SHOP</a>) down 9.01% at $91.58</li>
</ul>
<ul>
<li>V.F. Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VFC#NYSE">VFC</a>) down 8.77% at $14.95</li>
</ul>
<ul>
<li>Robinhood Markets Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) down 8.39% at $39.03</li>
</ul>
<ul>
<li>Viper Energy Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNOM#NASDAQ">VNOM</a>) down 8.41% at $42.08</li>
</ul>
<ul>
<li>SharkNinja Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SN#NYSE">SN</a>) down 8.09% at $81.25</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/04/44618089/trumps-tariffs-surprise-triggers-carnage-magnificent-7-set-to-wipe-out-nearly-700-billion-in-market-value">Markets Reel As Trump&#8217;s Tariffs Hit — Magnificent 7 Set To Shed Almost $700 Billion</a></li>
</ul>
Photo: Shutterstock.

Government

After-Hours Center

Movers

ASTS

DECK

DLTR

FIVE

HOOD

LULU

ONON

SHOP

VNOM

Trump Tariffs Trigger Sell-Off: On Holding, AST SpaceMobile, Lululemon, Shopify, Robinhood Tank

Ross Stores (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROST#NASDAQ">ROST</a>) has outperformed the market over the past 20 years by 3.72% on an annualized basis producing an average annual return of 11.85%. Currently, Ross Stores has a market capitalization of $43.43 billion. 
Buying $1000 In ROST: If an investor had bought $1000 of ROST stock 20 years ago, it would be worth $9,305.45 today based on a price of $132.09 for ROST at the time of writing.
<h3>Ross Stores's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743632128_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ROST

$1000 Invested In This Stock 20 Years Ago Would Be Worth This Much Today

Including this latest order, bookings for products from this OEM of natural gas turbines exceed $2.0 million in the first quarter of 2025.

Contracts

BWEN

Broadwind Secures Strategic Order For Precision Components Supporting Power Generation

In the last three months, 6 analysts have published ratings on Evercore (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVR#NYSE">EVR</a>), offering a diverse range of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $300.33, a high estimate of $339.00, and a low estimate of $252.00. This current average has decreased by 8.9% from the previous average price target of $329.67. 
<img src="https://www.benzinga.com/files/images/story/2025/1743631293_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The analysis of recent analyst actions sheds light on the perception of Evercore by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>James Yaro</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$252.00</td>
<td>$281.00</td>
</tr>
<tr>
<td>James Yaro</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$281.00</td>
<td>$321.00</td>
</tr>
<tr>
<td>Ryan Kenny</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$306.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Aidan Hall</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$339.00</td>
<td>$319.00</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$305.00</td>
<td>$318.00</td>
</tr>
<tr>
<td>Aidan Hall</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$319.00</td>
<td>$339.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Evercore. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Evercore compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Evercore's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Evercore's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/EVR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Evercore analyst ratings.</a>
<h2>Unveiling the Story Behind Evercore</h2>
Evercore is an independent investment bank that derives the majority of its revenue from financial advisory, including merger, acquisition, and restructuring advisory. It also has institutional equities trading, equity underwriting, and investment management businesses that account for around 20% of net revenue. The company was founded in 1996 and went public in 2006. Evercore had approximately 2,380 employees at the end of 2024, and about 75% of its revenue is derived from the United States.
<h3>Financial Insights: Evercore</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Positive Revenue Trend: Examining Evercore's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 24.38% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Financials sector.
Net Margin: Evercore's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 14.4%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Evercore's ROE excels beyond industry benchmarks, reaching 8.6%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Evercore's ROA excels beyond industry benchmarks, reaching 3.63%. This signifies efficient management of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.54, Evercore adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Breaking Down Evercore: 6 Analysts Share Their Views

In the last three months, 7 analysts have published ratings on Wolfspeed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>), offering a diverse range of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Wolfspeed, revealing an average target of $10.43, a high estimate of $17.00, and a low estimate of $6.00. A 32.1% drop is evident in the current average compared to the previous average price target of $15.36. 
<img src="https://www.benzinga.com/files/images/story/2025/1743631282_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of Wolfspeed among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brian Lee</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$8.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>George Gianarikas</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$10.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Vivek Arya</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$6.00</td>
<td>$9.50</td>
</tr>
<tr>
<td>Brian Lee</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$15.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Harsh Kumar</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$10.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Christopher Rolland</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$7.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Brian Lee</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$17.00</td>
<td>$19.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Wolfspeed. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Wolfspeed compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Wolfspeed's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Wolfspeed's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/WOLF/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Wolfspeed analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Discovering Wolfspeed: A Closer Look</h2>
Wolfspeed Inc is involved in the manufacturing of wide bandgap semiconductors. It is focused on silicon carbide and gallium nitride materials and devices for power and radio-frequency (RF) applications. The company serves applications such as transportation, power supplies, inverters, and wireless systems. Geographically, it derives a majority of its revenue from Europe and the rest from the United States, China, Hong Kong, Asia Pacific, and other regions.
<h3>Understanding the Numbers: Wolfspeed's Finances</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Decline in Revenue: Over the 3 months period, Wolfspeed faced challenges, resulting in a decline of approximately -13.39% in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Information Technology sector.
Net Margin: Wolfspeed's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -206.21% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Wolfspeed's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -74.33%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Wolfspeed's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -4.77%, the company showcases efficient use of assets and strong financial health.
Debt Management: Wolfspeed's debt-to-equity ratio stands notably higher than the industry average, reaching 12.01. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>The Significance of Analyst Ratings Explained</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

WOLF

Wolfspeed Stock: A Deep Dive Into Analyst Perspectives (7 Ratings)

Throughout the last three months, 4 analysts have evaluated Gevo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEVO#NASDAQ">GEVO</a>), offering a diverse set of opinions from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $10.79, a high estimate of $14.00, and a low estimate of $1.15. A decline of 4.6% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1743631272_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Gevo. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Manav Gupta</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$1.15</td>
<td>$3.25</td>
</tr>
<tr>
<td>Amit Dayal</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$14.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Amit Dayal</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$14.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Amit Dayal</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$14.00</td>
<td>$14.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Gevo. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Gevo compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Gevo's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Gevo's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/GEVO/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Gevo analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Get to Know Gevo Better</h2>
Gevo Inc is a renewable chemicals and biofuels company engaged in the development and commercialization of alternatives to petroleum-based products based on isobutanol produced from renewable feedstocks. Its operating segments are the Gevo segment, Renewable Natural Gas Segment, and the Agri-Energy segment. By its segments, it is involved in research and development activities related to the future production of SAF, commercial opportunities for other renewable hydrocarbon products and isobutanol, including the development of its biocatalysts, and the produces-pipeline quality methane gas captured from dairy cow manure.
<h3>Key Indicators: Gevo's Financial Health</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Gevo displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 30.32%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Energy sector.
Net Margin: Gevo's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -308.89%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -3.54%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Gevo's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -2.96%, the company showcases efficient use of assets and strong financial health.
Debt Management: Gevo's debt-to-equity ratio is below the industry average. With a ratio of 0.14, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Significance of Analyst Ratings Explained</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

GEVO

Expert Outlook: Gevo Through The Eyes Of 4 Analysts

In the latest quarter, 8 analysts provided ratings for Labcorp Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>), showcasing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $276.0, with a high estimate of $300.00 and a low estimate of $260.00. This current average has increased by 5.11% from the previous average price target of $262.57. 
<img src="https://www.benzinga.com/files/images/story/2025/1743631264_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A comprehensive examination of how financial experts perceive Labcorp Hldgs is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jamie Clark</td>
<td>Redburn Atlantic</td>
<td>Announces</td>
<td>Buy</td>
<td>$276.00</td>
<td>-</td>
</tr>
<tr>
<td>Ralph Giacobbe</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$300.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$260.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Jack Meehan</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$260.00</td>
<td>$271.00</td>
</tr>
<tr>
<td>Tycho Peterson</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$290.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Jack Meehan</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$271.00</td>
<td>$249.00</td>
</tr>
<tr>
<td>Kevin Caliendo</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$286.00</td>
<td>$293.00</td>
</tr>
<tr>
<td>Elizabeth Anderson</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$265.00</td>
<td>$260.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Labcorp Hldgs. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Labcorp Hldgs compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
To gain a panoramic view of Labcorp Hldgs's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/LH/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Labcorp Hldgs analyst ratings.</a>
<h2>Get to Know Labcorp Hldgs Better</h2>
Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing.
<h3>Labcorp Hldgs's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Over the 3 months period, Labcorp Hldgs showcased positive performance, achieving a revenue growth rate of 9.76% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Labcorp Hldgs's net margin excels beyond industry benchmarks, reaching 4.31%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 1.77%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Labcorp Hldgs's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 0.78%, the company showcases efficient use of assets and strong financial health.
Debt Management: Labcorp Hldgs's debt-to-equity ratio is below the industry average. With a ratio of 0.9, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: Simplified</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Laboratory Corporation Of America Holdings

Assessing Labcorp Hldgs: Insights From 8 Financial Analysts

Intra-Cellular Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) underwent analysis by 6 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $126.67, along with a high estimate of $132.00 and a low estimate of $100.00. This current average has increased by 7.65% from the previous average price target of $117.67. 
<img src="https://www.benzinga.com/files/images/story/2025/1743631256_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The analysis of recent analyst actions sheds light on the perception of Intra-Cellular Therapies by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$132.00</td>
<td>$132.00</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$132.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Sumant Kulkarni</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Hold</td>
<td>$132.00</td>
<td>$119.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$132.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>David Amsellem</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$132.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Hold</td>
<td>$100.00</td>
<td>$100.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Intra-Cellular Therapies. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Intra-Cellular Therapies compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Intra-Cellular Therapies's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Intra-Cellular Therapies's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ITCI/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Intra-Cellular Therapies analyst ratings.</a>
<h2>Unveiling the Story Behind Intra-Cellular Therapies</h2>
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. It maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.
<h3>Intra-Cellular Therapies: Delving into Financials</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Intra-Cellular Therapies's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 51.49%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Intra-Cellular Therapies's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -8.48%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Intra-Cellular Therapies's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -1.47%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Intra-Cellular Therapies's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -1.25%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.01.
<h2>Analyst Ratings: Simplified</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ITCI

Demystifying Intra-Cellular Therapies: Insights From 6 Analyst Reviews

Canadian Natural Res (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNQ#NYSE">CNQ</a>) has outperformed the market over the past 5 years by 20.0% on an annualized basis producing an average annual return of 36.31%. Currently, Canadian Natural Res has a market capitalization of $64.64 billion. 
Buying $1000 In CNQ: If an investor had bought $1000 of CNQ stock 5 years ago, it would be worth $4,657.78 today based on a price of $30.79 for CNQ at the time of writing.
<h3>Canadian Natural Res's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743631248_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 5 Years Ago, You Would Have This Much Today

11 analysts have shared their evaluations of BlackRock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLK#NYSE">BLK</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">6</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">6</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $1135.91, with a high estimate of $1275.00 and a low estimate of $971.00. Witnessing a positive shift, the current average has risen by 0.84% from the previous average price target of $1126.45.
<img src="https://www.benzinga.com/files/images/story/2025/1743631248_0_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A clear picture of BlackRock's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kenneth Worthington</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$1046.00</td>
<td>$1053.00</td>
</tr>
<tr>
<td>Brennan Hawken</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$1045.00</td>
<td>$1017.00</td>
</tr>
<tr>
<td>Mike Cyprys</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$1275.00</td>
<td>$1261.00</td>
</tr>
<tr>
<td>Aidan Hall</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$1180.00</td>
<td>$1160.00</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$1175.00</td>
<td>$1155.00</td>
</tr>
<tr>
<td>Kenneth Worthington</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$1053.00</td>
<td>$971.00</td>
</tr>
<tr>
<td>Brian Bedell</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$1275.00</td>
<td>$1215.00</td>
</tr>
<tr>
<td>Kenneth Worthington</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$971.00</td>
<td>$914.00</td>
</tr>
<tr>
<td>Aidan Hall</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$1160.00</td>
<td>$1225.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$1160.00</td>
<td>$1220.00</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$1155.00</td>
<td>$1200.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to BlackRock. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of BlackRock compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of BlackRock's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of BlackRock's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BLK/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on BlackRock analyst ratings.</a>
<h2>Unveiling the Story Behind BlackRock</h2>
BlackRock is the largest asset manager in the world, with $11.475 trillion in assets under management at the end of September 2024. Its product mix is fairly diverse, with 55% of managed assets in equity strategies, 26% in fixed income, 9% in multi-asset classes, 7% in money market funds, and 3% in alternatives. Passive strategies account for around two thirds of long-term AUM, with the company's ETF platform maintaining a leading market share domestically and on a global basis. Product distribution is weighted more toward institutional clients, which by our calculations account for around 80% of AUM. BlackRock is geographically diverse, with clients in more than 100 countries and more than one third of managed assets coming from investors domiciled outside the US and Canada.
<h3>BlackRock's Financial Performance</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: BlackRock displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 22.59%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Financials sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: BlackRock's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 29.42%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): BlackRock's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 3.77%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): BlackRock's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 1.23%, the company may face hurdles in achieving optimal financial returns.
Debt Management: BlackRock's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.3.
<h2>The Basics of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down BlackRock: 11 Analysts Share Their Views

In the current session, the stock is trading at $236.32, after a 3.00% increase. Over the past month, Applied Industrial Techs Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIT#NYSE">AIT</a>) stock increased by 1.52%, and in the past year, by 21.65%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2025/1743631217_0.png" alt="Past Year Chart" />

<h3>How Does Applied Industrial Techs P/E Compare to Other Companies?</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Applied Industrial Techs has a better P/E ratio of 23.22 than the aggregate P/E ratio of 21.21 of the Trading Companies &amp; Distributors industry. Ideally, one might believe that Applied Industrial Techs Inc. might perform better in the future than it's industry group, but it's probable that the stock is overvalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1743631217_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

Markets

P/E Ratio Insights for Applied Industrial Techs

WMPN

Mid Penn Bancorp, William Penn Bancorporation Secure Shareholder Approvals For Merger

Vail Resorts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTN#NYSE">MTN</a>) has outperformed the market over the past 20 years by 1.41% on an annualized basis producing an average annual return of 9.55%. Currently, Vail Resorts has a market capitalization of $6.06 billion. 
Buying $100 In MTN: If an investor had bought $100 of MTN stock 20 years ago, it would be worth $619.11 today based on a price of $162.33 for MTN at the time of writing.
<h3>Vail Resorts's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743630327_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Vail Resorts Stock In The Last 20 Years

A sweeping new wave of tariffs unveiled by President Donald Trump on Wednesday triggered a sharp selloff during the after hours of trading as the scope and scale of the trade duties exceeded <a href="https://www.benzinga.com/25/04/44616760/donald-trump-sets-reciprocal-tariffs-on-key-trade-partners-in-historic-policy-shock">Wall Street's worst-case expectations.</a>
The president framed the move as a long-overdue correction to decades of trade imbalance, instituting what he called a "reciprocal tariff rate," set at 50% of what trading partners charge the United States, but also factoring in non-tariff barriers like currency manipulation, value-added taxes and outright import bans.
While Trump had telegraphed his intention to "rebalance" U.S. trade policy, the specific duty levels, some of which reached into the mid-30% range with key trading partners, jolted investors.
Under the new framework, China, which Trump said imposes tariffs as high as 67% on American goods, will now face reciprocal U.S. duties of approximately 37%. The European Union, which applies a 39% combined rate including VATs, will be subject to a 20% U.S. tariff. Japan, with an estimated 46% trade barrier, now faces a 24% duty on exports to the U.S.
Canada and Mexico, two major trading partners, were notably excluded from the tariff program — a move that suggests Trump may be preserving the U.S.-Mexico-Canada Agreement, at least for now.
The White House confirmed that new trade tariffs will take effect on April 9. 
<h3 class="wp-block-heading">Tariffs Spark After-Hours Chaos: Index Futures Dive</h3>
The market&#8217;s reaction was swift and brutal. By 5:10 p.m. ET, futures on the S&amp;P 500 dropped 2.5%, while Nasdaq 100 futures fell 3.3%. Dow Jones Industrial Average contracts lost 1.4% and the Russell 2000 futures collapsed by 4.7%. 
Losses were broad-based. Every major sector of the S&amp;P 500 was in the red, with Consumer Discretionary Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>) and Technology Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>) down about 3%.
As risk appetite evaporated, gold prices climbed. Futures on the yellow metal gained 1.1%, extending their year-to-date advance as investors sought shelter from escalating geopolitical and trade tensions.
<h3 class="wp-block-heading">Tech Megacaps Bear the Brunt</h3>
The Magnificent Seven stocks, the market's dominant tech names, are on track to lose a combined $685 billion.
Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) was the biggest laggard, down 6.6% and projected to erase $221.7 billion in market value.
 Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) lost 4.7%, a drop equivalent to $127.2 billion. Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) fell 5.1%, and Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) slid nearly 6%, as traders repositioned for a potentially more inflationary and protectionist economic environment.
Here's the breakdown of projected market cap losses with the tech elite group:
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Name</th>
<th>Market Cap ($B)</th>
<th>Post-Mkt % Chg</th>
<th>Projected Loss ($B)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Apple Inc.</td>
<td>3364.8</td>
<td>-6.59%</td>
<td>-221.7</td>
</tr>
<tr>
<td>Microsoft Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>)</td>
<td>2842.7</td>
<td>-1.99%</td>
<td>-56.6</td>
</tr>
<tr>
<td>NVIDIA Corporation</td>
<td>2694.6</td>
<td>-4.72%</td>
<td>-127.2</td>
</tr>
<tr>
<td>Amazon.com, Inc. </td>
<td>2079.0</td>
<td>-5.06%</td>
<td>-105.2</td>
</tr>
<tr>
<td>Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>)</td>
<td>1923.7</td>
<td>-3.09%</td>
<td>-59.4</td>
</tr>
<tr>
<td>Meta Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>)</td>
<td>1480.5</td>
<td>-4.16%</td>
<td>-61.6</td>
</tr>
<tr>
<td>Tesla, Inc. </td>
<td>910.7</td>
<td>-5.86%</td>
<td>-53.4</td>
</tr>
<tr>
<td>Total</td>
<td>—</td>
<td>—</td>
<td>-685.1</td>
</tr>
</tbody>
</table>
</figure>
According to <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data, the steepest decliners in the aftermarket session included:
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Name</th>
<th>Chg %</th>
</tr>
</thead>
<tbody>
<tr>
<td>RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>)</td>
<td>-24.41%</td>
</tr>
<tr>
<td>Penske Automotive Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAG#NYSE">PAG</a>)</td>
<td>-22.47%</td>
</tr>
<tr>
<td>Lululemon Athletica Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>)</td>
<td>-12.51%</td>
</tr>
<tr>
<td>Hess Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HES#NYSE">HES</a>)</td>
<td>-11.61%</td>
</tr>
<tr>
<td>The Gap, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPS#NYSE">GPS</a>)</td>
<td>-11.60%</td>
</tr>
<tr>
<td>lululemon athletica inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>)</td>
<td>-10.82%</td>
</tr>
<tr>
<td>Five Below, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVE#NASDAQ">FIVE</a>)</td>
<td>-10.38%</td>
</tr>
</tbody>
</table>
</figure>
Major gainers were: 
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Name</th>
<th>Chg %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dillard&#8217;s, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DDS#NYSE">DDS</a>)</td>
<td>+4.36%</td>
</tr>
<tr>
<td>Certara, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERT#NASDAQ">CERT</a>)</td>
<td>+4.16%</td>
</tr>
<tr>
<td>Federal Realty Investment Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FRT#NYSE">FRT</a>)</td>
<td>+3.78%</td>
</tr>
<tr>
<td>Reinsurance Group of America, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RGA#NYSE">RGA</a>)</td>
<td>+2.79%</td>
</tr>
<tr>
<td>Ferguson Enterprises Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FERG#NASDAQ">FERG</a>)</td>
<td>+2.57%</td>
</tr>
<tr>
<td>Church &amp; Dwight Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHD#NYSE">CHD</a>)</td>
<td>+2.48%</td>
</tr>
<tr>
<td>L3Harris Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LHX#NYSE">LHX</a>)</td>
<td>+2.33%</td>
</tr>
</tbody>
</table>
</figure>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44610548/trumps-auto-tariffs-could-crush-demand-blow-26-billion-hole-in-industry-profits">Trump&#8217;s Auto Tariffs Could Crush Demand, Blow $26 Billion Hole In Industry Profits</a></li>
</ul>
Image created using photos from Shutterstock.

Large Cap

Macro Economic Events

Regulations

Broad U.S. Equity ETFs

Economics

ETFs

AAPL

AMZN

CERT

FERG

GOOGL

MSFT

NVDA

TSLA

Select Sector SPDR-Consumer Discretionary

Markets Reel As Trump's Tariffs Hit — Magnificent 7 Set To Shed Almost $700 Billion

Press Releases

Biodexa Strengthens Management Team - Appointment of Dr Gary A. Shangold as Chief Medical Officer

Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis

Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status

Biodexa Pharmaceuticals PLC to Present at the Emerging Growth Conference on February 19, 2025

Presenting on the Emerging Growth Conference 79 Day 1 on February 18 Register Now

Presenting on the Emerging Growth Conference 79 Day 2 on February 19 Register Now

Legal

Biodexa Announces Allowance of U.S. Patent Covering  Oral Rapamycin Nanoparticle Preparations ("eRapa") and Use

Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP

Health Care

Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP

With Fast Track Designation in Hand, a Successful Protocol Discussion with FDA, and CROs in Place, Biodexa is on Track to Initiate its Funded Phase 3 Trial in FAP Next Quarter

AEMD

ANPCY

ASPI

ATWT

BDRX

BENF

BIXT

BNRG

BOSC

CSE:HG

ELRRF

GOSS

GOVX

HDRSF

HGRAF

IMRN

IPWR

JAGX

LGVN

MESO

PBEGF

RGBP

SIGY

SWKH

TSX:CNL

TSX:ELO

TSX:TXP

TSXV:HI

TSXV:WRLG

UCAR

USEG

WRLGF

XXII

Apollomics

Aptevo Therapeutics

Entero Therapeutics

Genprex

GRI Bio

Onconetix

Polyrizon

Protagenic Therapeutics, Inc. - Common Stock

Protagenic Therapeutics

TransCode Therapeutics, Inc. - Common Stock

TransCode Therapeutics

Scorpius Holdings

Salarius Pharmaceuticals, Inc. - Common Stock

Salarius Pharmaceuticals

Vincerx Pharma

Windtree Therapeutics, Inc. - Common Stock

Windtree Therapeutics

ZyVersa Therapeutics, Inc. - Common Stock

ZyVersa Therapeutics

Ladenburg Thalmann

Screenshot 2025-03-18 at 8.36.36 PM

Biotech

General

Fast Track Designation Secured, Successful Protocol Discussion With FDA And CROs Confirmed, Biodexa On Track To Initiate Funded Phase 3 FAP Trial Next Quarter

Untitled design - 2025-02-11T232646.924

Following Positive Phase 2 Results And Orphan Drug Designation, Biodexa&#39;s FAP Drug Receives FDA Fast Track Status

Image

Gaining Momentum, Biodexa Is Advancing Two Recent Acquisitions Through The Clinic

Untitled design - 2024-10-16T235234.675

Biodexa&#39;s MX-110 Continues To Show Promise In Recurrent Glioblastoma (rGBM), The Deadliest Brain Cancer

Screenshot 2024-07-10 at 9.15.35 PM

Biodexa Announces Additional Positive Results Of Phase 2 Trial Of eRapa In Treatment Of Precancerous Polyps In The GI Tract – Now 12-Month Data

Screenshot 2024-06-03 at 5.21.04 PM

Promising Phase 2 Results For Biodexa&#39;s eRapa™ Indicates Hope For FAP Patients Who Otherwise Have A 100% Lifetime Risk Of Colorectal Cancer

Screenshot 2024-05-08 at 7.48.00 PM

Biodexa Looks To Prevent Or Delay The Worst Outcomes For Adolescents And Young Adults With Devastating Precancerous Condition

Untitled design - 2024-03-28T172702.605

Biodexa&#39;s MTX110 Shows Promise In Extending Life Expectancy Against Aggressive Brain Cancers

Redington 2_29

PowerShares Dynamic Financial Sector Portfolio

Biodexa Takes Aim At Type 1 Diabetes With Innovative Drug Candidate Tolimidone

Comments

Biodexa Pharmaceuticals

Interés en corto

Biodexa Pharmaceuticals (NASDAQ:BDRX) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL